| Name | ch5138303 |
|---|---|
| Synonyms |
4-((4-Amino-6-(5-chloro-1,3-dihydrobenzo[de]isochromen-6-yl)-1,3,5-triazin-2-yl)thio)butanamid
Butanamide, 4-[[4-amino-6-(5-chloro-1H,3H-naphtho[1,8-cd]pyran-6-yl)-1,3,5-triazin-2-yl]thio] 4-[(4-Amino-6-[7-chloro-3-oxatricyclo[7.3.1.0(5,13)] trideca-1(13),5,7,9,11-pentaen-8-yl]-1,3,5-triazin-2-yl)sulfanyl]butanamide 4-[[4-Amino-6-(5-chloro-1H,3H-naphtho[1,8-cd]pyran-6-yl)-1,3,5-triazin-2-yl]thio]butanamide CH5138303 //BP CH5138303_Hsp90 4-[4-amino-6-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazin-2-ylsulfanyl]butanamide CH5138303cas |
| Description | CH5138303 is a potent and orally active Hsp90 inhibitor. CH5138303 shows high binding affinity for N-terminal Hsp90α, with Kd of 0.52 nM. CH5138303 shows potent anti-proliferative activity against human cancer cell lines (HCT116 and NCI-N87), with IC50 values of 0.098 and 0.066 μM, respectively. CH5138303 shows high oral bioavailability in mice (F=44.0%). CH5138303 shows potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model[1][2]. |
|---|---|
| Related Catalog | |
| Target |
HSP90α:0.52 nM (Kd) |
| In Vitro | When used in combination with FLC, CH5138303 shows antifungal activitiy against azole-resistant C. albicans, with a FICI (fractional inhibitory concentration index) of 0.500[2]. |
| In Vivo | CH5138303 (SCID mice bearing NCI-N87 cells, 0-50 mg/kg, Orally, once daily for 11 days) shows potent antitumor efficacy with TGI (tumor growth inhibition) of 136% and a median effective dose (ED50) of 3.9 mg/kg without significant loss of body weight[1]. |
| References |
| Molecular Formula | C19H18ClN5O2S |
|---|---|
| Molecular Weight | 415.89700 |
| Exact Mass | 415.08700 |
| PSA | 142.31000 |
| LogP | 4.59670 |
| Storage condition | -20℃ |